A Randomized, Open-Label, Controlled, Multicenter Phase III Study of Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone Versus Platinum-based Chemotherapy for First-line Treatment in Subjects With PD-L1 Positive Relapsed or Advanced NSCLC
Latest Information Update: 03 Jun 2022
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 14 Sep 2021 Status changed from not yet recruiting to recruiting.
- 14 Sep 2021 Results (data cut off: Dec 11, 2020; n=25) presented at the 2021 World Conference on Lung Cancer
- 07 May 2020 Planned initiation date changed from 15 Feb 2020 to 15 Jun 2020.